Total synthesis of the isoquinolinium metabolite ETM-204 of Trabectedin

Christian Lembacher-Fadum¹ · Simon Gissing¹ · Georg Pour² · Rolf Breinbauer¹

Received: 2 August 2021 / Accepted: 27 August 2021
© The Author(s) 2021

Abstract

Ecteinasidin-743 (Trabectedin, Trabectedin[®], Yondelis[®]) is a synthetically obtained pharmaceutical drug originally isolated from a marine tunicate. Trabectedin is used for the chemotherapy of soft-tissue sarcoma and ovarian cancer. The isoquinolinium metabolite ETM-204 has been found in biotransformation and degradation studies of Trabectedin. We report the first total synthesis of ETM-204 and its full spectroscopic characterization confirming the postulated structure. Central elements of the 12-step synthesis starting from 2-methyl-6-nitrophenol are a Cu-mediated conversion of an iodoarene to a phenol, a Skattebøl-formylation, and a modified Pomeranz–Fritsch cyclization to assemble the isoquinoline ring. The pH-dependence of its visual absorbance could be clarified.

Graphic abstract

Keywords Cyclization · Heterocycles · Indicator dye · Medicinal chemistry · Ullman coupling

Introduction

Ecteinasidin-743 (ET-743) is a marine alkaloid originally isolated from the Caribbean tunicate *Ecteinasidia turbinata*. ET-743 binds covalently to guanine residues in the minor groove of the DNA double helix, which triggers a series of downstream events resulting in potent antitumor activity. ET-743 is marketed as Trabectedin[®] (Yondelis[®]) for the treatment of soft-tissue carcinoma and ovarian cancer. This remarkable biological activity with its unique mechanism of action together with its complex structure has made it an attractive target for total synthesis. Impressive total syntheses have been reported by Corey [1], Fukuyama [2,

3], Danishefsky [4, 5], Zhu [6, 7], Chen [8], Williams [9], Ma [10], and several synthetic studies towards its synthesis have been undertaken [11]. Commercial production involves the semi-synthesis starting from cyanosafraicin B [12, 13].

In the course of the clinical development of Trabectedin, studies have been undertaken, which investigated the metabolism and degradation of this complex natural product [14–17]. Several metabolites have been identified and characterized via HPLC–MS. In Scheme 1 we outline the degradation pathway, which leads to the formation of ETM-204 and other metabolites proposed in the literature [14–17]. To confirm the structure of the key metabolite, which also represents a degradation product of the drug substance and product, we isolated ETM-204 and partially characterized it on the one hand and sought out to synthesize ETM-204 and confirm its structure by full spectroscopic characterization and make it accessible for biological testing and as reference standard on the other hand.

✉ Rolf Breinbauer
breinbauer@tugraz.at

¹ Institute of Organic Chemistry, Graz University of Technology, Graz, Austria

² Ever Valinject GmbH, Unterach Am Attersee, Austria

Scheme 1 Main degradation products of trabectedin proposed in the literature [14–17]

Results and discussion

Isolation and characterization of degradation product ETM-204

To verify and characterize ETM-204, one of the main degradation products, sufficient amounts of this substance needed to be isolated from a stressed Trabectedin solution. Thermal stress applied to a methanolic solution was found to be most efficient to generate high amounts of the target substance. Ideally, Trabectedin solution was incubated for 4 d at 60 °C yielding the degradation product in approx. 35–40% (based on relative area by HPLC). Higher temperatures and/or longer incubation time did not improve the yield. Using semi-preparative HPLC 2 mg of material was purified which was subjected to NMR analysis for structure elucidation and confirmation.

Additionally HPLC–MS experiments using stressed Trabectedin solution were conducted to further characterize the degradation product. Signals from ESI positive mode at m/z 204 as well as m/z 189 and m/z 161 indicate the pseudo-molecular ion ($M+H$), the loss of 15 Da (m/z 204 $\rightarrow$ 189) representing a methyl group and 43 Da (m/z 204 $\rightarrow$ 161) representing a CH_3CHN fragment all shown in Fig. 1. These results are in agreement with published data from Reid [14].

Fig. 1 Mass spectrometric fragments used for structural annotation of ETM-204

Total synthesis of ETM-204

To confirm the structure and obtain sufficient quantities for analytical and biological studies we pursued a total synthesis of ETM-204 (Scheme 2).

As starting material for our synthesis, we used commercially available 2-methyl-6-nitrophenol and converted it into nitroanisole **1** via Williamson ether synthesis using 1.5 eq iodomethane and 2.0 eq potassium carbonate in DMF at 23 °C. This reaction delivered **1** in excellent 99% yield after aqueous workup and sufficient purity, which allowed to use the crude product of **1** directly in a reduction of the nitro group with 5.0 eq iron powder in an acetic acid/water mixture to produce *o*-anisidine **2**. Although the

Scheme 2 Synthetic route towards Trabectedin degradation product ETM-204

phase separation during aqueous workup took some time because of formation of an emulsion, the reaction provided 98% of the desired compound **2** as a red-brown oil, which was already pure according to NMR and used without further treatment. A colorless product sample was obtained via distillation with a Kugelrohr apparatus.

Next, we planned to convert the amino group of compound **2** into phenol-OH by first forming the corresponding aryl diazonium salt **3a** and subsequent replacement by a hydroxy group via heating up the acidic aqueous solution to obtain 3-methylguaiacol (**4**) directly. While the diazotation worked reliably, we failed to convert the diazonium species **3a** to compound **4**, as it either did not react at all, or decomposed after longer reaction times. Therefore, we decided to use iodo compound **3** as an intermediate, which was formed in 96% yield after addition of 2.1 eq sodium iodide solution to the diazonium intermediate **3a** and stirring at 23 °C

overnight. The conversion of iodoarene **3** into phenol **4** was planned using copper salts as catalyst and water as a nucleophile [18]. The best yield (70%) was achieved using a procedure of Xiao et al., with Cu(OH)₂ in combination with glycolic acid as ligand [19].

The next step involved the *ortho*-formylation of phenol **4**. First attempts using SnCl₄/paraformaldehyde [20] or hexamethylenetetramine [21, 22] failed for this substrate. Next, we tried a procedure of Hofsløkken and Skattebøl, who described a convenient method for the *ortho*-formylation of phenols using MgCl₂/Et₃N and paraformaldehyde in dry MeCN [23]. First test reactions were encouraging, but the yield was very low. We finally achieved the best results with fresh batches of MgCl₂ and paraformaldehyde, which have been dried for 90 min in oil-pump vacuum before they were used, and isolated **5** in moderate 48% yield.

Scheme 3 Unsuccessful cyclization strategies **A** via Pictet–Spengler reaction of **6a** and **B** via Pomeranz–Fritsch reaction directly from intermediate **6b**

Our initial strategy towards the *N*-methylated isoquinoline scaffold was based on the synthesis of compound **6a** via reductive amination, followed by a Pictet–Spengler reaction with glyoxal (Scheme 3). As previous publications indicated that suitable reaction conditions could lead directly to the oxidized form of the heterocycle [24], we tried several conditions (variation of the temperature, changing the amount of glyoxal solution, using formic acid, acetic acid or 1,4-dioxane/HCl). Unfortunately, despite these efforts we could not detect any cyclized product. As an alternative cyclization method, we attempted a Pomeranz–Fritsch reaction [25] by condensing aldehyde **5** with aminoacetaldehyde dimethyl acetal to Schiff base **6b** (Scheme 3). Unfortunately, it was not possible to cyclize **6b** directly under acidic conditions as described by Woodward and Doering for a related, but less complex substrate [26]. Therefore, we followed a modified cyclization strategy of Birch and coworkers [27] by first reducing imine **6b** with sodium borohydride to amine **6**, which was directly *N*-tosylated without further purification to obtain **7** in excellent 99% yield over 2 steps. As many by-products were detected in the cyclization attempts of **7** we speculated that we could improve the selectivity of the reaction, by protecting the phenol-OH as a benzyl ether (Scheme 2). Indeed cyclization of **8** in 1,4-dioxane/6 M aqueous HCl at 110 °C led to cyclized product **9** in 48% yield. The expected elimination of the tosyl group did not proceed under acidic conditions, probably because of the

electron donating effect of the benzyloxy substituent in position 8, which renders the proton in position 1 less acidic [27]. However, this could be easily overcome by treating **9** with potassium *tert*-butoxide in *tert*-butanol to form isoquinoline **10** in 87% yield (Scheme 2).

After deprotection of **10** via catalytic hydrogenation, using an H-cube[®] continuous-flow hydrogenation reactor with a 10% Pd on charcoal cartridge, **11** was obtained in moderate 55% yield after flash column chromatography, where also unreacted starting material **10** was collected and subjected to a second hydrogenation cycle via H-cube[®].

With purified isoquinoline **11** in hand, a few test reactions were performed to find the best conditions for the methylation of the nitrogen atom. We had concerns that the phenolic OH could be methylated as well, which would complicate the purification of the final product. This issue could be avoided by exclusion of any addition of a base. Even with a large excess of iodomethane exclusive *N*-methylation was observed. Pure target compound ETM-204 was obtained in quantitative yield as an iodide salt by evaporation of the volatiles and subsequent drying in oil-pump vacuum (Scheme 2).

The final product was orange-colored as a solid and solutions were yellow (dissolved in methanol or chloroform), which was in contrast to the deep red color of the material isolated from degradation studies described above. Furthermore, all aromatic protons in our ¹H spectrum were

Fig. 2 pH-dependent behavior of ETM-204 in methanolic solution and the corresponding ^1H NMR spectra. HPLC traces of the samples are provided in the supporting information

significantly shifted downfield compared to the ^1H spectrum of Reid et al. [14], while the HPLC retention times of synthetic and isolated products were identical. To understand this different appearance, we performed experiments to study the acid/base behavior of ETM-204. Figure 2A shows the ^1H NMR spectrum of the synthesized compound (with iodide as counter ion) and its solution in methanol. Next, we dissolved a small amount of our compound in 1 M NaOH (orange solution), and extracted it with chloroform, where the organic phase immediately turned red. After phase separation, drying of the organic phase over Na_2SO_4 and filtration, the volatiles were removed under reduced pressure and a dark red solid was obtained, which was dissolved in methanol- d_4 and a ^1H NMR spectrum was recorded (Fig. 2B). The proton shifts of this betaine compound were in full alignment with the values previously described in literature [14]. After addition of a droplet of 4 M HCl in 1,4-dioxane to the red solution, the color immediately turned yellow again (Fig. 2C). After evaporation of the volatiles, a third ^1H spectrum was recorded, which showed the same shifts as the initial spectrum and reflects the phenolic form of ETM-204.

Conclusion

In summary, we have successfully synthesized the central Trabectedin metabolite ETM-204 in a 12-step synthesis, assigned its structure via NMR spectroscopy and confirmed it with authentic material resulting from degradation studies. The synthesis started from commercially available 2-methyl-6-nitrophenol, which was converted into 2-methoxy-3-methylphenol (**4**) in four steps. *ortho*-Formylation with paraformaldehyde and $\text{MgCl}_2/\text{Et}_3\text{N}$ provided 2-hydroxy-3-methoxy-4-methylbenzaldehyde (**5**), which was further subjected to a reductive amination, followed by an N-tosylation. Key step of the synthesis was the cyclization to 1,2-dihydroisoquinoline derivative **9**, which only succeeded after protection of the phenol-OH with a benzyl group. After aromatization and deprotection, isoquinoline **11** was finally N-methylated with an excess of iodomethane to yield ETM-204 as iodide. We could show that ETM-204 shows a pH-dependent behavior and can either exist as a cationic species in acidic pH or as a betaine under basic pH, which has to be considered when investigating its properties.

Experimental

Reactions were carried out under air, unless indicated otherwise. For inert reactions, standard Schlenk techniques under an inert atmosphere of N₂ or Ar and anhydrous solvents were used. The described nuclear resonance spectra were acquired with the following instruments: Bruker AVANCE III with autosampler: 300.36 MHz ¹H NMR, 75.53 MHz ¹³C NMR; chemical shifts δ [ppm] are referenced to residual protonated solvent signals as internal standard: CDCl₃: δ = 7.26 ppm (¹H), 77.16 ppm (¹³C); methanol-*d*₄: δ = 3.31 ppm (¹H), 49.00 ppm (¹³C). Signal multiplicities are abbreviated as bs (broad singlet), d (doublet), dd (doublet of doublet), dt (doublet of triplet), m (multiplet), s (singlet), t (triplet), and q (quadruplet). The deuterated solvent, the chemical shifts δ in ppm (parts per million), and the coupling constants *J* in Hertz (Hz) are given. Deuterated solvents for nuclear resonance spectroscopy were purchased from Euriso-top®. Analytical thin layer chromatography (TLC) was performed on Merck silica gel 60, F₂₅₄ plates and spots were visualized by UV-light (λ = 254 and/or 366 nm), or by treatment with cerium ammonium molybdate solution (CAM: 5.0 g Ce(IV)SO₄, 50 g (NH₄)₂MoO₄, 50 cm³ concentrated H₂SO₄ in 450 cm³ water) or KMnO₄ solution (3.0 g KMnO₄ and 20.0 g K₂CO₃ dissolved in 300 cm³ H₂O and 5 cm³ of 5% aqueous NaOH). Flash column chromatography was performed using silica gel 60 from Macherey–Nagel (40–63 μ m particle size) at an air pressure of ~1.5 bar. Analytical HPLC measurements were performed on an Agilent Technologies 1200 Series HPLC system with 1260 HiP Degasser G4225A, binary pump SL G1312, autosampler HiP-ALS SL G1367C, thermostated column compartment TCC SL G1316B, multiple wavelength detector G1365C MWD SL with deuterium lamp (λ = 190–400 nm) and subsequent connected mass detector (Agilent Technologies 6120 Quadrupole LC/MS) with an electrospray ionization (ESI) source. The components were separated on a RP Agilent Poroshell 120 EC-C18 column (3.0 × 100 mm, 2.7 μ m particles) with a Merck LiChroCART® 4–4 pre-column. Signals were detected at 210 or 254 nm. As mobile phase acetonitrile (VWR HiPerSolv, HPLC–MS grade) and water (Barnstead NANOpure®, ultrapure water system) with 0.05% trifluoroacetic acid (TFA) was used. The following standard method was used: Column oven: 40 °C, flow rate 0.7 cm³/min; 0–0.5 min CH₃CN/0.05% TFA = 2:98 (v/v), 0.5–10.0 min linear increase to CH₃CN/0.05% TFA = 100:0 (v/v), 10.0–12.0 min hold CH₃CN/0.05% TFA = 100:0 (v/v), 12.5–13.0 min return to initial conditions. High-resolution mass spectrometry (HRMS): all HRMS measurements were done at Vienna BioCenter, using the following procedure: sample spectra were acquired by data-dependent high-resolution tandem mass spectrometry on a QExactive Focus (Thermo Fisher Scientific, Germany). The electrospray ionization potential

was set to +3.5 or –3.0 kV, the sheath gas flow was set to 20, and an auxiliary gas flow of 5 was used. Samples were diluted with an appropriate solvent (methanol or chloroform) and 1 mm³ was injected on a SeQuant® ZIC®-pHILIC HPLC column (Merck, 100 × 2.1 mm; 5 μ m; 100 Å; peek coated; equipped with a guard column). The separation solvent (A: ACN, B: 25 mM ABC) was delivered through an Ultimate 3000 HPLC system (Thermo Fisher Scientific, Germany) with a flow rate of 100 mm³ min^{–1} and appropriate gradients were used for proper sample elution. Acetonitrile (ACN) HiPerSolv CHROMANORM® for HPLC–Supergradient was obtained from VWR Chemicals, methanol Optima® LC/MS Grade from Fisher Chemicals, ammonium hydrogen carbonate for LC–MS LiChropur were purchased from Merck, chloroform Plus for HPLC from Sigma–Aldrich, and H₂O was obtained from a Milli-Q® Advantage A10 water purification system (Merck). Melting points were measured on a MEL-TEMP® apparatus with integrated microscopical support from Electrothermal in open capillary tubes. Reported values are uncorrected. Hydrogenation experiments were performed using the H-Cube® continuous-flow hydrogenation unit (HC-2.SS) from ThalesNano Inc. running with a Knauer Smartline pump 100 and equipped with a 10 cm³ ceramic pump head. As hydrogenation catalyst 10% Pd/C catalyst cartridges were used (ThalesNano Inc., THS01111, 10% Pd/C CatCart™). Chemicals were purchased from the companies ABCR, ACROS Organics, Alfa Aesar, Brenntag, Fisher Scientific, Fluka, Merck, Roth, Sigma Aldrich or VWR and were used without further purification, unless otherwise stated. All solvents were purchased from the above-mentioned companies and were used without further purification unless otherwise stated. For reactions where moisture was excluded, absolute solvents were used. For that purpose, the purchased solvents were dried using the following methods and stored in brown 1 dm³ Schlenk bottles under argon and over activated molecular sieves. For analytical applications solvents with analytical grade were purchased. Absolute DMF, MeCN, and MeOH were purchased in anhydrous quality and stored over activated molecular sieves (3 Å: MeCN, MeOH; 4 Å: DMF) under argon. Dichloromethane: CH₂Cl₂ (stabilized with EtOH) was first heated under reflux over P₄O₁₀ for 5 h, then heated under reflux over CaH₂ for 5 h and distilled under argon atmosphere into a brown 1 dm³ Schlenk bottle containing activated 4 Å molecular sieves. Absolute Et₃N was obtained by refluxing over CaH₂ and distilling into a 1 dm³ Schlenk bottle containing activated 4 Å molecular sieves. 1,4-Dioxane was distilled and stored over KOH.

Isolation of ETM-204 by degradation of Trabectedin

20 mg Trabectedin were placed into a 10 cm³ glass vial, dissolved in 8 cm³ MeOH, closed and put into an oven

for 4 d at 60 °C. Afterwards the reaction was stopped by placing the solution into a fridge. Semi-preparative chromatography of stressed solutions was conducted on an Agilent 1260 Infinity II instrument with quaternary pump G7111B, sampler G7129A, thermostatic column compartment G7116B and DAD G7115A using a Zorbax SB-Phenyl, 250×9.6 mm with 5 µm particles column. Respective fractions were collected automatically during several runs using a G1364 Agilent fraction collector. Mobile phase A was an aqueous solution with 16 mM ammonium formate (Fluka, LC-grade) and 26 mM formic acid (Merck, ACS Reag Ph Eur.). As mobile phase B acetonitrile was used (VWR, LC-grade). First step of the run consisted of 10 min isocratic phase at a composition of 82% A and 18% B and a flow rate of 4.5 cm³/min. After that the column was washed by changing to 90% mobile phase B for 11 min followed by an equilibration step of 5 min. Collected fractions were combined and concentrated using evaporator GeneVac EZ-2 (Bartelt). Remaining residues were resuspended in 1.5 cm³ dichloromethane (VWR, GC-grade). The supernatant was carefully removed from the precipitate and put into a fresh HPLC-vial. Again, material was evaporated to complete dryness to yield 2 mg and stored at 2–8 °C until NMR analysis. HPLC–MS analysis of solutions from degradation study was performed on an Agilent 1290 Infinity instrument with binary pump G4220A, sampler GG4226A, thermostatic column compartment G1316C and DAD G4212A coupled with a Sciex QTRAP 4500 operating in positive electron spray mode (ESI+). Components were separated on a Zorbax SB-Phenyl, 150×4.6 mm with 1.8 µm particles column. The same mobile phases were used as described above but in MS-grade quality. At a flow rate of 0.8 cm³/min initial conditions were 15% mobile phase B increasing to 27% after 45 min. A second steeper gradient was implemented until 75 min up to 65% B followed by an equilibration step for 12 min at initial conditions.

2-Methoxy-1-methyl-3-nitrobenzene (1) A dried and argon-flushed 100 cm³ Schlenk-flask with magnetic stirring bar was charged with 5.66 g 2-methyl-6-nitrophenol (37.0 mmol, 1.0 eq), which were then dissolved in 70 cm³ abs. DMF forming a yellow solution. Then 10.2 g K₂CO₃ (73.9 mmol, 2.0 eq) and 3.50 cm³ iodomethane (55.4 mmol, 1.5 eq) were added resulting in a red suspension, which was stirred for 60 h at 23 °C. The suspension, which had turned orange, was diluted with 300 cm³ EtOAc, poured into a 1000 cm³ separation funnel and washed with half-saturated NaCl solution (5×300 cm³) and brine (1×200 cm³). The resulting yellow organic layer was dried over Na₂SO₄, filtered and concentrated on a rotary evaporator furnishing 6.13 g **1** (36.7 mmol, 99%) as a red oil. $R_f=0.48$ (cyclohexane/EtOAc = 10:1 (v/v); UV/KMnO₄); ¹H NMR

(300 MHz, CDCl₃): $\delta=7.63$ (d, $J=7.4$ Hz, 1H, Ar–H), 7.41 (d, $J=7.2$ Hz, 1H, Ar–H), 7.10 (t, $J=7.9$ Hz, 1H, Ar–H), 3.90 (s, 3H, OCH₃), 2.37 (s, 3H, CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): $\delta=151.8$ (C_{Ar}–OCH₃), 144.5 (C_{Ar}–NO₂), 135.7 (C_{Ar}–H), 134.6 (C_{Ar}–CH₃), 123.9 (C_{Ar}–H), 123.0 (C_{Ar}–H), 62.0 (OCH₃), 16.2 (CH₃) ppm.

2-Methoxy-3-methylaniline (2) In an inert 500 cm³ round-bottom flask equipped with a Schlenk adapter and a magnetic stirring bar 6.00 g 2-methoxy-1-methyl-3-nitrobenzene (**1**, 35.9 mmol, 1.0 eq) were dissolved in 180 cm³ glacial acetic acid and 18 cm³ dist. H₂O. 10.0 g Fe powder (180 mmol, 5.0 eq) were added, the Schlenk adapter connected to a bubbler and the reaction mixture stirred for 17 h at 23 °C. The resulting grey-blue suspension was poured into a 2 dm³ Erlenmeyer flask and neutralized with 400 cm³ satd. K₂CO₃-solution under ice cooling. After further dilution with 500 cm³ dist. H₂O the reaction mixture was transferred into a 2 dm³ separation funnel. The reaction mixture was extracted with 350 cm³ CH₂Cl₂ upon which a third intermediate phase was formed, which was collected separately. The aqueous phase was again extracted with 350 cm³ CH₂Cl₂ and the intermediate phase was extracted with 150 cm³ CH₂Cl₂. The combined organic phases were dried over Na₂SO₄, filtered and the solvent removed on a rotary evaporator (at water bath temperature ≤ 30 °C). The resulting 4.84 g red-brown oil of **2** (35.3 mmol, 98%) was used in the next step without further purification. $R_f=0.16$ (cyclohexane/EtOAc = 10:1 (v/v); UV/KMnO₄); ¹H NMR (300 MHz, CDCl₃): $\delta=6.83$ (t, $J=7.7$ Hz, 1H, Ar–H), 6.59 (“t”, $J=7.1$ 2H, Ar–H), 3.76 (s, 3H, OCH₃, overlapping with bs, 2H, NH₂), 2.28 (s, 3H, CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): $\delta=145.9$ (C_{Ar}–OCH₃), 139.9 (C_{Ar}–NH₂), 131.2 (C_{Ar}–CH₃), 124.5 C_{Ar}–H), 120.9 (C_{Ar}–H), 113.9 (C_{Ar}–H), 59.8 (OCH₃), 15.9 (CH₃) ppm.

1-Iodo-2-methoxy-3-methylbenzene (3) In an inert 500 cm³ round-bottom flask equipped with a Schlenk adapter and a magnetic stirring bar 4.56 cm³ 2-methoxy-3-methylaniline (**2**, 34.6 mmol, 1.0 eq) were dissolved 125 cm³ H₂SO₄ (10% in H₂O, 134.9 mmol, 3.9 eq) and cooled in an ice bath to 0 °C. With a syringe pump a solution of 5.01 g NaNO₂ (72.6 mmol, 2.1 eq) in 35 cm³ dist. H₂O were added dropwise with a rate of 40 cm³/h. After completed addition the resulting slightly brownish solution was stirred for another 45 min at 0 °C. Then, a solution of 10.9 g NaI (72.6 mmol, 2.1 eq) in 35 cm³ dist. H₂O was added with a syringe pump at a flowrate of 4 cm³/min, upon which immediately the solution turned dark-brown and foam formation was observed. After removal of the ice bath the septum of the flask was replaced with a bubbler and the reaction mixture was stirred for 19 h at 23 °C. The resulting two-phase solution (dark brown aqueous phase and black oil) were

transferred into a 1000 cm³ separation funnel and extracted with CH₂Cl₂ (2 × 200 cm³). The combined organic phases were then washed with 1.8 M Na₂S₂O₄ solution (3 × 200 cm³), dist. H₂O (1 × 200 cm³), and brine (1 × 200 cm³), dried over Na₂SO₄, filtrated and concentrated on a rotary evaporator resulting in 8.28 g **3** (33.4 mmol, 96%) and dark brown oil, which was used in the next step without further purification. ¹H NMR (300 MHz, CDCl₃): δ = 7.61 (d, *J* = 7.8 Hz, 1H, Ar-H), 7.14 (d, *J* = 7.4 Hz, 1H, Ar-H), 6.75 (t, *J* = 7.7 Hz, 1H, Ar-H), 3.78 (s, 3H, OCH₃), 2.35 (s, 3H, CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ = 158.2 (C_{Ar}-OCH₃), 137.3 (C_{Ar}-H), 132.5 (s, 1C, C_{Ar}-CH₃), 131.7 (s, 1C, C_{Ar}-H), 126.0 (s, 1C, C_{Ar}-H), 92.1 (s, 1C, C_{Ar}-I), 60.3 (s, 1C, C_{Ar}-OCH₃), 17.1 (s, 1C, CH₃) ppm.

2-Methoxy-3-methylphenol (4) A 250 cm³ three-necked round-bottom flask with a gas adapter, reflux condenser, bubbler, and a magnetic stir bar was charged with a solution of 8.20 g 1-iodo-2-methoxy-3-methylbenzene (**3**, 33.1 mmol, 1.0 eq) in 50 cm³ DMSO. To the brown solution were subsequently added 50 cm³ NaOH solution (4.0 mol/dm³ in H₂O), 3.02 g glycolic acid (39.7 mmol, 1.2 eq) and 1.29 g copper(II) hydroxide (13.2 mmol, 0.4 eq). The suspension was stirred under nitrogen atmosphere for 64 h at 120 °C (oil bath). After cooling to 23 °C the dark brown reaction mixture was diluted with 100 cm³ H₂O, acidified with 6 M HCl to pH = 3, transferred to a 500 cm³ separation funnel and extracted with EtOAc (4 × 100 cm³). The combined organic phases were washed with half-saturated NaCl solution (200 cm³) and brine (2 × 200 cm³), dried over Na₂SO₄, filtered, and the solvent was carefully removed under reduced pressure (*T* ≤ 30 °C). The crude product (6.83 g) was purified via flash column chromatography (410 g SiO₂; cyclohexane/EtOAc = 10:1 (v/v)) and 3.22 g (23.3 mmol, 70%) **4** were isolated as brown oil. *R*_f = 0.20 (cyclohexane/EtOAc = 10:1 (v/v); UV/KMnO₄); ¹H NMR (300 MHz, CDCl₃): δ = 6.93 (t, *J* = 7.8 Hz, 1H, Ar-H), 6.82 (d, *J* = 6.8 Hz, 1H, Ar-H), 6.71 (d, *J* = 7.4 Hz, 1H, Ar-H), 5.76 (bs, 1H, OH), 3.81 (s, 3H, OCH₃), 2.32 (s, 3H, CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ = 149.0 (C_{Ar}-OH), 145.6 (C_{Ar}-OCH₃), 131.0 (C_{Ar}-CH₃), 124.7 (C_{Ar}-H), 122.6 (C_{Ar}-H), 113.3 (C_{Ar}-H), 60.7 (OCH₃), 15.9 (CH₃) ppm.

2-Hydroxy-3-methoxy-4-methylbenzaldehyde (5) An inert 250 cm³ three-necked round-bottom flask equipped with reflux condenser, bubbler, Schlenk line adapter, and magnetic stirring bar was charged with 3.29 g anhydrous MgCl₂ (34.5 mmol, 1.5 eq) and 4.70 g paraformaldehyde (156 mmol, 6.8 eq), which were then dried for 90 min in oil-pump vacuum. Then 60 cm³ abs. MeCN, 3.18 g 2-methoxy-3-methylphenol (**4**, 23.0 mmol, 1.0 eq), and 12.1 cm³ abs. triethylamine (87.4 mmol, 3.8 eq) were added and the reaction mixture was stirred for 19 h at 90 °C in an oil bath. After

full conversion 50 cm³ H₂SO₄ (10% in H₂O) were added to the yellow suspension, and the mixture was transferred into a separation funnel and extracted with CH₂Cl₂ (4 × 90 cm³). The combined organic phases were dried over Na₂SO₄, filtered, and the solvent was carefully removed under reduced pressure (*T* ≤ 30 °C). The crude product (4.18 g) was purified via flash column chromatography (420 g SiO₂; cyclohexane/EtOAc = 20:1 (v/v)) to yield 1.84 g (11.1 mmol, 48%) of compound **6** as a pale brown oil. *R*_f = 0.46 (cyclohexane/EtOAc = 10:1 (v/v); UV/CAM); ¹H NMR (300 MHz, CDCl₃): δ = 11.14 (s, 1H, OH), 9.82 (s, 1H, CHO), 7.19 (d, *J* = 7.9 Hz, 1H, Ar-H), 6.81 (d, *J* = 7.9 Hz, 1H, Ar-H), 3.89 (s, 3H, OCH₃), 2.33 (s, 3H, CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ = 196.2 (CHO), 154.9 (C_{Ar}-OH), 146.3 (C_{Ar}-OCH₃), 141.0 (C_{Ar}-CH₃), 128.2 (s, 1C, C_{Ar}-H), 121.9 (C_{Ar}-H), 120.4 (C_{Ar}-CHO), 60.2 (OCH₃), 16.9 (CH₃) ppm.

2-Methoxy-3-methyl-6-[(methylamino)methyl]phenol (6a) An inert 25 cm³ Schlenk tube with magnetic stirring bar was charged with a solution of 535 mg 2-hydroxy-3-methoxy-4-methylbenzaldehyde (**5**, 3.22 mmol, 1.0 eq) in 4.0 cm³ abs. MeOH and 441 mm³ methylamine solution (33% in abs. EtOH, 3.54 mmol, 1.1 eq) were added. The yellow solution was stirred for 60 min at 23 °C, and after full conversion (reaction control via TLC; cyclohexane/EtOAc = 10:1 (v/v); *R*_f = 0.10; UV/CAM) the reaction mixture was cooled to 0 °C (ice bath) and treated with 122 mg NaBH₄ (3.22 mmol, 1.0 eq). The ice bath was removed and the pale yellow solution was stirred at 23 °C for additional 45 min. Subsequently, the volatiles were removed under reduced pressure. The colorless residue was partitioned between 15 cm³ EtOAc and 15 cm³ H₂O in a 50 cm³ separation funnel and the aqueous phase was extracted with EtOAc (4 × 15 cm³). The combined organic phases were dried over Na₂SO₄, filtered, and the solvent was removed under reduced pressure. The crude product (566 mg) was dried in oil-pump vacuum and purified via flash column chromatography (57 g SiO₂; CH₂Cl₂/MeOH = 15:1 + 1% NH₄OH (v/v)) to yield 501 mg (2.76 mmol, 86%) of **6a** as a pale brown oil. *R*_f = 0.20 (CH₂Cl₂/MeOH = 15:1 + 1% NH₄OH (v/v); UV/KMnO₄); ¹H NMR (300 MHz, CDCl₃): δ = 6.64 (d, *J* = 7.6 Hz, 1H, Ar-H), 6.57 (d, *J* = 7.6 Hz, 1H, Ar-H), 3.94 (s, 2H, CH₂), 3.86 (s, 3H, OCH₃), 2.47 (s, 3H, NCH₃), 2.25 (s, 3H, C_{Ar}-CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ = 151.3 (C_{Ar}-OCH₃), 146.3 (C_{Ar}-OH), 131.0 (C_{Ar}-CH₃), 123.0 (C_{Ar}-H), 121.3 (C_{Ar}-CH₂), 120.2 (C_{Ar}-H), 59.9 (OCH₃), 54.4 (CH₂), 35.1 (NCH₃), 15.9 (C_{Ar}-CH₃) ppm.

6-[(2,2-Diethoxyethyl)amino]methyl]-2-methoxy-3-methylphenol (6, C₁₅H₂₅NO₄) An inert 50 cm³ round-bottom flask with Schlenk adapter and magnetic stirring bar was charged with a solution of 1.78 g

2-hydroxy-3-methoxy-4-methylbenzaldehyde (**5**, 10.7 mmol, 1.0 eq) in 13 cm³ abs. MeOH and 1.86 cm³ aminoacetaldehyde diethyl acetal (12.9 mmol, 1.2 eq) were added. The yellow solution was stirred for 30 min at 23 °C, and after full conversion (reaction control via TLC; cyclohexane/EtOAc = 10:1 (v/v); R_f = 0.17; UV/KMnO₄) the reaction mixture was cooled to 0 °C (ice bath) and treated portionwise with 0.61 g NaBH₄ (16.1 mmol, 1.5 eq). After completion of the gas evolution (~5 min) the ice bath was removed and the pale yellow solution was stirred at 23 °C for additional 30 min. Subsequently, the volatiles were removed under reduced pressure. The yellow residue was partitioned between 40 cm³ EtOAc and 20 cm³ H₂O in a 100 cm³ separation funnel and the aqueous phase was extracted with EtOAc (2 × 20 cm³). The combined organic phases were dried over Na₂SO₄, filtered, and the solvent was removed under reduced pressure. After drying for 3 h in oil-pump vacuum, the red-brown oil (3.03 g, 10.7 mmol, quant.) was directly used in the next step without further purification. R_f = 0.08 (cyclohexane/EtOAc = 5:1 (v/v); UV/KMnO₄); ¹H NMR (300 MHz, CDCl₃): δ = 6.64 (d, J = 7.6 Hz, 1H, Ar-H), 6.57 (d, J = 7.7 Hz, 1H, Ar-H), 4.61 (t, J = 5.5 Hz, 1H, CH₂CH), 3.98 (s, 2H, C_{Ar}-CH₂NH), 3.85 (s, 3H, OCH₃), 3.75–3.62 (m, 2H, CH₂CH₃), 3.61–3.43 (m, 2H, CH₂CH₃'), 2.77 (d, J = 5.5 Hz, 2H, CH₂CH), 2.24 (s, 3H, C_{Ar}-CH₃), 1.20 (t, J = 7.0 Hz, 6H, 2 × CH₂CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ = 151.2 (C_{Ar}-OCH₃), 146.4 (C_{Ar}-OH), 131.3 (C_{Ar}-CH₃), 123.1 (C_{Ar}-H), 121.4 (C_{Ar}-CH₂), 120.5 (C_{Ar}-H), 101.6 (CH₂CH), 62.9 (2C, 2 × CH₂CH₃), 60.0 (OCH₃), 52.3 (C_{Ar}-CH₂), 50.8 (CH₂CH), 16.0 (C_{Ar}-CH₃), 15.5 (2C, 2 × CH₂CH₃) ppm; HR-ESI-MS: calcd. m/z for [C₁₅H₂₅NO₄ + H]⁺ 284.1856, found 284.1857.

N-(2,2-Diethoxyethyl)-N-(2-hydroxy-3-methoxy-4-methylbenzyl)-4-methylbenzenesulfonamide (7, C₂₂H₃₁NO₆S) An inert 50 cm³ round-bottom flask with Schlenk adapter and magnetic stirring bar was charged with a solution of 2.75 g compound **6** (9.70 mmol, 1.0 eq) in 13 cm³ abs. CH₂Cl₂. Then 1.94 g *p*-toluenesulfonic acid (10.2 mmol, 1.05 eq) and 0.81 g sodium bicarbonate (9.7 mmol, 1.0 eq) were added to the solution, the flask was equipped with a bubbler, and the reaction mixture was stirred at 23 °C for 24 h, after which time the volatiles were removed under reduced pressure. The crude product (4.91 g) was purified via flash column chromatography (500 g SiO₂; cyclohexane/EtOAc = 3:1 (v/v)) to give the desired product (3.95 g, 9.03 mmol, 93%) as a colorless oil. R_f = 0.42 (cyclohexane/EtOAc = 3:1 (v/v); UV/KMnO₄); ¹H NMR (300 MHz, CDCl₃): δ = 7.68 (d, J = 8.2 Hz, 2H, Ts-H), 7.26 (d, J = 8.6 Hz, 2H, Ts-H), 6.84 (d, J = 7.8 Hz, 1H, Ar-H), 6.62 (d, J = 7.9 Hz, 1H, Ar-H), 6.32 (s, 1H, OH), 4.60 (t, J = 5.4 Hz, 1H, CH₂CH), 4.49 (s, 2H, C_{Ar}-CH₂N), 3.76 (s, 3H, OCH₃), 3.67–3.62 (m, 2H, CH₂CH₃), 3.52–3.35 (m,

2H, CH₂CH₃'), 3.31 (d, J = 5.4 Hz, 2H, CH₂CH), 2.42 (s, 3H, C_{Ar}-CH₃ of Ts), 2.26 (s, 3H, C_{Ar}-CH₃), 1.14 (t, J = 7.0 Hz, 6H, 2 × CH₂CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ = 147.8 (C_{Ar}-OCH₃), 145.9 (C_{Ar}-OH), 143.2 (C-SO₂), 137.5 (C_{Ar}-CH₃ of Ts), 130.9 (C_{Ar}-CH₃), 129.6 (2C, C_{Ar}-H of Ts), 127.4 (2C, C_{Ar}-H of Ts), 125.8 (C_{Ar}-H), 121.8 (C_{Ar}-H), 120.3 (C_{Ar}-CH₂), 102.1 (CH₂CH), 63.4 (2C, 2 × CH₂CH₃), 60.5 (OCH₃), 50.0 (CH₂CH), 48.0 (C_{Ar}-CH₂), 21.6 (CH₃ of Ts), 15.9 (CH₃), 15.3 (2C, CH₂CH₃) ppm; HR-ESI-MS: calcd. m/z for [C₂₂H₃₁NO₆S-H]⁻ 436.1799, found 436.1804.

N-[2-(Benzyloxy)-3-methoxy-4-methylbenzyl]-N-(2,2-diethoxyethyl)-4-methylbenzenesulfonamide (8, C₂₉H₃₇NO₆S) An inert 100 cm³ round-bottom flask with Schlenk adapter and magnetic stirring bar was charged with a solution of 3.79 g **7** (8.66 mmol, 1.0 eq) in 43 cm³ abs. DMF. Then 1.80 g potassium carbonate (13.0 mmol, 1.5 eq) and 1.54 cm³ benzyl bromide (13.0 mmol, 1.5 eq) were added to the colorless solution and the suspension was stirred at 40 °C (oil bath) overnight. The reaction mixture was transferred into a 250 cm³ separation funnel, diluted with 130 cm³ EtOAc, and washed with H₂O (5 × 90 cm³) and brine (90 cm³). The organic phase was dried over Na₂SO₄, filtered, and the solvent was removed under reduced pressure. The crude product (4.75 g) was purified via flash column chromatography (475 g SiO₂; cyclohexane/EtOAc = 7:1 (v/v)) to yield 4.25 g (8.05 mmol, 93%) of **8** as a colorless oil. R_f = 0.31 (cyclohexane/EtOAc = 7:1 (v/v); UV/KMnO₄); ¹H NMR (300 MHz, CDCl₃): δ = 7.63 (d, J = 8.2 Hz, 2H, Ts-H), 7.47–7.28 (m, 5H, Bn-H), 7.23 (d, J = 8.2 Hz, 2H, Ts-H), 6.95 (d, J = 7.9 Hz, 1H, Ar-H), 6.85 (d, J = 7.9 Hz, 1H, Ar-H), 4.98 (s, 2H, Bn-CH₂), 4.52 (t, J = 5.4 Hz, 1H, CH₂CH), 4.42 (s, 2H, C_{Ar}-CH₂N), 3.78 (s, 3H, OCH₃), 3.65–3.45 (m, 2H, CH₂CH₃), 3.43–3.26 (m, 2H, CH₂CH₃'), 3.22 (d, J = 5.4 Hz, 2H, CH₂CH), 2.41 (s, 3H, CH₃ of Ts), 2.26 (s, 3H, CH₃), 1.05 (t, J = 7.0 Hz, 6H, 2 × CH₂CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ = 151.4 (C_{Ar}-OCH₃), 149.9 (C_{Ar}-OBn), 143.1 (C-SO₂), 137.7 (Bn-C_q), 137.6 (C_{Ar}-CH₃ of Ts), 131.8 (C_{Ar}-CH₃), 129.6 (2C, C_{Ar}-H of Ts), 128.7 (C_q-Ar), 128.5 (2C, C_{Ar}-H of Bn), 128.4 (2C, C_{Ar}-H of Bn), 128.1 (C_q-Ar), 127.4 (2C, C_{Ar}-H of Ts), 125.9 (C_{Ar}-H), 124.4 (C_{Ar}-H), 102.0 (CH₂CH), 74.9 (Bn-CH₂), 63.1 (2C, 2 × CH₂CH₃), 60.3 (OCH₃), 50.7 (CH₂CH), 47.7 (C_{Ar}-CH₂), 21.6 (CH₃ of Ts), 15.9 (CH₃), 15.3 (2C, 2 × CH₂CH₃) ppm; HR-ESI-MS: calcd. m/z for [C₂₉H₃₇NO₆S + NH₄]⁺ 545.2680, found 545.2682.

8-(Benzyloxy)-7-methoxy-6-methyl-2-tosyl-1,2-dihydroisoquinoline (9, C₂₅H₂₅NO₄S) A 250 cm³ round-bottom flask with reflux condenser and magnetic stirring bar was charged with a solution of 4.13 g **8** (7.82 mmol, 1.0 eq) in 80 cm³ 1,4-dioxane. After addition of 6.5 cm³ 6 M HCl

(39 mmol, 5.0 eq) the mixture was heated to 110 °C (oil bath) and heated under reflux for 6.5 h. The brown solution was cooled to 23 °C, the solvent removed under reduced pressure, and the crude residue (3.95 g) dried in oil-pump vacuum. Purification via flash column chromatography (475 g SiO₂, cyclohexane/EtOAc = 10:1 (v/v)) provided 1.65 g (3.79 mmol, 48%) **9** as a colorless solid. R_f = 0.27 (cyclohexane/EtOAc = 10:1 (v/v); UV/KMnO₄); m.p.: 104–109 °C; ¹H NMR (300 MHz, CDCl₃): δ = 7.64 (d, J = 8.2 Hz, 2H, Ts–H), 7.50–7.30 (m, 5H, Bn–H), 7.25 (d, J = 8.1 Hz, 2H, Ts–H), 6.69 (d, J = 7.7 Hz, 1H, NCH=CH), 6.54 (s, 1H, Ar–H), 5.72 (d, J = 7.8 Hz, 1H, NCH=CH), 4.94 (s, 2H, Bn–CH₂), 4.44 (s, 2H, NCH₂), 3.80 (s, 3H, OCH₃), 2.39 (s, 3H, CH₃ of Ts), 2.20 (s, 3H, CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ = 150.9 (C_{Ar}–OCH₃), 147.6 (C_{Ar}–OBn), 144.0 (C_q of Ts), 137.3 (C_q of Bn), 134.9 (C_{SO}), 131.6 (C_{Ar}–CH₃), 129.8 (2C, C_{Ar}–H of Ts), 128.7 (2C, C_{Ar}–H of Bn), 128.6 (2C, C_{Ar}–H of Bn), 128.4 (C_{Ar}–H of Bn), 127.3 (2C, C_{Ar}–H of Ts), 126.7 (C_q–Ar), 125.6 (NCH=CH), 122.3 (C_{Ar}–H), 119.7 (C_q–Ar), 109.6 (NCH=CH), 75.2 (Bn–CH₂), 60.4 (OCH₃), 42.2 (NCH₂), 21.6 (CH₃ of Ts), 15.8 (CH₃) ppm; HR-ESI-MS: calcd. m/z for [C₂₅H₂₅NO₄S + H]⁺ 436.1577, found 436.1579.

8-(Benzyloxy)-7-methoxy-6-methylisoquinoline (10, C₁₈H₁₇NO₂) A 50 cm³ round-bottom flask containing 1.65 g **9** (3.79 mmol, 1.0 eq) was equipped with a Schlenk adapter and magnetic stirring bar and purged with Ar (3 ×). The solid was partially dissolved in warm *t*-BuOH (15 cm³) and 2.34 g potassium *tert*-butoxide (20.9 mmol, 5.5 eq) were added. The mixture was heated to 80 °C (oil bath) and the resulting brown solution was stirred for 16 h, after which time it was cooled to 23 °C and diluted with 30 cm³ H₂O. The product was extracted with an appropriate amount of EtOAc (3 ×), and the combined organic phases were washed with brine, dried over Na₂SO₄ and filtered. The solvent was removed under reduced pressure and the crude product (988 mg) dried in oil-pump vacuum. Purification via flash column chromatography (100 g SiO₂, cyclohexane/EtOAc = 3:1 (v/v)) provided 925 mg (3.31 mmol, 87%) **10** as a colorless solid. R_f = 0.25 (cyclohexane/EtOAc = 3:1 (v/v); UV/CAM); m.p.: 68–70 °C; ¹H NMR (300 MHz, CDCl₃): δ = 9.45 (s, 1H, H-1), 8.42 (d, J = 5.7 Hz, 1H, H-3), 7.61–7.29 (m, 7H, Ar–H), 5.22 (s, 2H, CH₂), 3.99 (s, 3H, OCH₃), 2.48 (s, 3H, CH₃) ppm; ¹³C NMR (75.5 MHz, CDCl₃): δ = 149.3 (C_{Ar}–OCH₃), 147.4 (C-1), 146.4 (C_{Ar}–OBn), 142.6 (C-3), 138.2 (C_q–CH₃), 137.1 (C_q–CH₂), 133.4 (C_q–Ar), 128.8 (2C, C_{Ar}–H of Bn), 128.6 (2C, C_{Ar}–H of Bn), 128.5 (C_{Ar}–H of Bn), 123.9 (C_q–Ar), 122.9 (C-5), 119.3 (C-4), 75.9 (CH₂), 60.7 (OCH₃), 17.4 (CH₃) ppm; HR-ESI-MS: calcd. m/z for [C₁₈H₁₇NO₂ + H]⁺ 280.1332, found 280.1334.

7-Methoxy-6-methylisoquinolin-8-ol (11, C₁₁H₁₁NO₂) Compound **10** (850 mg, 3.04 mmol) was dissolved in 75 cm³ MeOH and the pale yellow solution was subjected to catalytic hydrogenation using an H-cube[®] continuous-flow reactor (ThalesNano Inc.) at 1.0 cm³/min and 2.8 × 10⁵ Pa equipped with a 10% Pd/C cartridge at 30 °C. The solvent was removed under reduced pressure and the crude product (736 mg) was purified via flash column chromatography (75 g SiO₂, CH₂Cl₂/MeOH = 20:1 (v/v)) to provide 318 mg (1.68 mmol, 55%) of **11** as a salmon-colored solid. R_f = 0.17 (CH₂Cl₂/MeOH = 20:1 (v/v); UV/CAM); m.p.: 188 °C; ¹H NMR (300 MHz, methanol-*d*₄): δ = 9.37 (s, 1H, H-1), 8.24 (d, J = 5.9 Hz, 1H, H-3), 7.56 (d, J = 5.8 Hz, 1H, H-4), 7.18 (s, 1H, H-6), 3.82 (s, 3H, OCH₃), 2.46 (d, J = 0.6 Hz, 3H, CH₃) ppm; ¹³C NMR (75.5 MHz, methanol-*d*₄): δ = 147.7 (C-7), 147.1 (C-8), 144.4 (C-7), 141.6 (C-3), 139.8 (C-6), 135.0 (C-4a), 121.6 (C-8a), 121.2 (C-4), 118.9 (C-5), 61.0 (OCH₃), 17.2 (CH₃) ppm; HR-ESI-MS: calcd. m/z for [C₁₁H₁₁NO₂ + H]⁺ 190.0863, found 190.0862.

8-Hydroxy-7-methoxy-2,6-dimethylisoquinolinium iodide (ETM-204, C₁₂H₁₄INO₂) A 25 cm³ round-bottom flask was charged with a solution of 300 mg 7-methoxy-6-methylisoquinolin-8-ol (**11**, 1.59 mmol, 1.0 eq) in 7.9 cm³ abs. MeOH. Iodomethane (987 mm³, 15.9 mmol, 10 eq) were added to the stirred orange solution (partially undissolved) and the tightly closed flask was stirred at 23 °C for 27 h. The resulting orange solution was concentrated via a Schlenk line by condensating the volatiles in an intermediate cooling trap and the remaining yellow solid was dried in oil-pump vacuum to give 523 mg (1.58 mmol, quant.) of the final compound ETM-204, which did not require further purification. R_f = 0.30 (strong tailing; CH₂Cl₂/MeOH = 10:1 (v/v); UV/CAM); m.p.: 201–203 °C (decomposition); ¹H NMR (300 MHz, methanol-*d*₄): δ = 9.73 (s, 3H, H-1), 8.32 (dd, J = 6.8, 1.2 Hz, 1H, H-3), 8.16 (d, J = 6.8 Hz, 1H, H-4), 7.56 (s, 1H, H-5), 4.46 (s, 3H, N–CH₃), 3.88 (s, 3H, OCH₃), 2.60 (s, 3H, CH₃) ppm; ¹³C NMR (75.5 MHz, methanol-*d*₄): δ = 149.7 (C-8), 148.0 (C-7), 146.9 (C-6), 146.6 (C-1), 135.1 (2C, C-3 and C-4a), 125.5 (C-4), 120.9 (C-8a), 119.9 (C-5), 61.3 (OCH₃), 48.3 (N–CH₃), 17.8 (CH₃) ppm; HR-ESI-MS: calcd. m/z for [C₁₂H₁₄NO₂]⁺ 204.1019, found 204.1019.

Acknowledgements We thank Ing. Carina Illaszewicz-Trattner and Prof. Dr. Jörg Weber for assistance in NMR measurements and NAWI Graz for financial support.

Funding Open access funding provided by Graz University of Technology.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Corey EJ, Gin DY, Kania RS (1996) *J Am Chem Soc* 118:9202
- Endo A, Yanagisawa A, Ab M, Tohma S, Kan T, Fukuyama T (2002) *J Am Chem Soc* 124:6552
- Kawagishi F, Toma T, Inui T, Yokoshima S, Fukuyama T (2013) *J Am Chem Soc* 135:13684
- Zheng S, Chan C, Furuuchi T, Wright BJD, Zhou B, Guo J, Danishefsky SJ (2006) *Angew Chem Int Ed* 45:1754
- Zheng S, Chan C, Furuuchi T, Wright BJD, Zhou B, Guo J, Danishefsky SJ (2006) *Angew Chem* 118:1786
- Chen J, Chen X, Bois-Choussy M, Zhu J (2005) *J Am Chem Soc* 128:87
- Chen J, Chen X, Willot M, Zhu J (2006) *Angew Chem Int Ed* 45:8028
- Jia J, Chen R, Jia Y, Gu H, Zhou Q, Chen X (2019) *J Org Chem* 84:13696
- Fishlock D, Williams RM (2008) *J Org Chem* 73:9594
- He W, Zhang Z, Ma D (2019) *Angew Chem Int Ed* 58:3972
- Avendano C, de la Cuesta E (2010) *Chem Eur J* 16:9722
- Cuevas C, Perez M, Martin M, Chicharro J, Fernandez-Rivas C, Flores M, Francesch A, Gallego P, Zarzuelo M, De La Calle F, Garcia J, Polanco C, Rodriguez I, Manzanares I (2000) *Org Lett* 2:2545
- Menchaca R, Martínez V, Rodríguez A, Rodríguez N, Flores M, Gallego P, Manzanares I, Cuevas C (2003) *J Org Chem* 68:8859
- Reid JM, Kuffel MJ, Ruben SL, Morales JJ, Rinehart KL, Squillace DP, Ames MM (2002) *Clin Cancer Res* 8:2952
- Brandon EFA, Sparidans RW, Guijt KJ, Löwenthal S, Meijerman I, Beijnen JH, Schellens JHM (2006) *Investigat New Drugs* 24:3
- Beumer JH, Rademaker-Lakhai JM, Rosing H, Hillebrand MJX, Bosch TM, Lopez-Lazaro L, Schellens JHM, Beijnen JH (2007) *Cancer Chemother Pharmacol* 59:825
- Vermeir M, Hemeryck A, Cuyckens F, Francesch A, Bockx M, Van Houdt J, Steemans K, Mannens G, Aviles P, De Coster R (2009) *Biochem Pharmacol* 77:1642
- Cohen T, Dietz AG Jr, Miser JR (1977) *J Org Chem* 42:2053
- Xiao Y, Xu Y, Cheon H-S, Chae J (2013) *J Org Chem* 78:5804
- Werlé C, Yin C-JM, Heinemann FW, Hauser C, Meyer K (2017) *Tetrahedron Lett* 58:2715
- Larrow JF, Jacobsen EN (2004) *Org Synth Coll* 10:96
- Duff JC, Bills EJ (1934) *J Chem Soc* 1305. <https://pubs.rsc.org/en/content/articlelanding/1932/JR/jr9320001987>
- Hofsløkken NU, Skattebøl L (1999) *Acta Chem Scand* 53:258
- Wang Y-X, Wang L, Xu Y-N, Li Y-H, Jiang J-D, Si S-Y, Li Y-B, Ren G, Shan Y-Q, Hong B, Song D-Q (2011) *Eur J Med Chem* 46:1066
- Pomeranz C (1893) *Monatsh Chem* 14:116
- Woodward RB, Doering WE (1945) *J Am Chem Soc* 67:860
- Birch AJ, Jackson AH, Shannon PVR (1974) *J Chem Soc. Perkin Trans 1*:2185

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.